• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management



Patients with rosacea who were treated with CollaGenex Pharmaceuticals' Periostat (doxycycline hyclate) showed continuous improvement during a 16-week Phase III trial, the firm reported. Among the 134 patients who received Periostat or placebo, Periostat-treated patients experienced a significantly greater reduction in the number of inflammatory lesions, according to a preliminary data analysis.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.